Natera, Inc. (NASDAQ:NTRA) Receives $165.88 Consensus Price Target from Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have been assigned an average recommendation of “Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. Sixteen research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $170.94.

A number of brokerages recently weighed in on NTRA. TD Cowen boosted their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird lifted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Morgan Stanley increased their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. boosted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Chartwell Investment Partners LLC grew its stake in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Cerity Partners LLC boosted its holdings in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after buying an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Natera in the third quarter worth approximately $385,000. Everence Capital Management Inc. bought a new position in shares of Natera in the fourth quarter valued at $573,000. Finally, First Turn Management LLC acquired a new stake in shares of Natera during the 3rd quarter valued at $19,760,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Down 3.5 %

NTRA stock opened at $162.31 on Monday. The firm has a market cap of $21.43 billion, a price-to-earnings ratio of -92.22 and a beta of 1.66. Natera has a 1-year low of $69.74 and a 1-year high of $183.00. The firm has a fifty day moving average price of $167.98 and a two-hundred day moving average price of $145.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.